Italian Association Amici di Raoul Follereau (AIFO)

Contact

General

Project Support

Alliances & Links

Resources & Training

ARCHIVES OF LEPROSY MAILING LIST
Archives of recent messages from Leprosy Mailing List (LML) managed by Dr Salvatore Noto.

Over the past few years, LML moderated by Dr Noto has become one of the most important online resource for promoting discussions about leprosy. For joining this mailing list kindly send an email to Dr. Salvatore Noto: salvatore.notoathsanmartino.it  (substitute at with @ in the email address)

Leprosy Mailing List – December 14th, 2006

 

Ref.:     How valid are any of these figures?

From:   Ryan T. J., Oxford, UK


  

 

 

Dear Salvatore,

 

I  find Soma Banajee's comments (LML, Dec. 10th, 2006) interesting.  I have been involved in a number of studies of Routes into Care in this country.  "Sufferers" from acute discomfort want instant care and will follow all routes.  For chronic illness the Government services are usually supplemented by other routes.  One always has to ask the participant in any study "have you taken this route into care, not for this disease but for any other concurrent problem?”

 

Leprosy is commonly not diagnosed when first seen by any route.  The habit of Dermatologists to take a biopsy if in doubt about any disease is a safeguard.  Like India the private sector and complimentary and alternative medicine (CAM) (Chinese, Indian systems and homeopathy) are much used for skin disease and praised for not making a skin diagnosis but a holistic constitutional even cosmic one.  We have only 460 dermatologists, few do much private practice, only a handful admit to prescribing other systems of medicine but a guesstimate is that many will use (CAM) for discomfort in themselves.  As to declaring for Government statistics one only has to look at STIs to see that the Private Sector and CAM are not especially compliant with the rules.

 

I write all this because reviewers of Al Wakeel and My "impressions" wont publish without controls and all the other things needed for proof.  Studies in the UK are hard enough and very expensive, but have been done and passed peer review.  Studies in India would be exorbitantly expensive to get the evidence one would like and in India I would prefer to spend the money on patient care.

 

The other diseases I study is Lymphatic Filariasis and all these issues are similarly expressed especially in India.  The main issue is not to believe that elimination in India is any where near even a Public Health requirement.

 

Terence Ryan

 

 

<< BACK TO LML ARCHIVE INDEX

 

AIFO, Via Borselli 4-6, 40135 Bologna, Italy
Tel: +390-51-4393.211 Fax: +390-51-434046 Email: info@aifo.it